Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026

Eli Lilly’s shares surged roughly 39% last year as sales momentum from its tirzepatide products (Mounjaro for diabetes and Zepbound for weight loss) helped cement expectations for a near-$100 billion obesity drug market by decade’s end. Viking Therapeutics, a pre-revenue biotech, is pitching VK2735 (injectable and oral dual GIP/GLP‑1 agonists) in late-stage development after a phase‑2 injectable trial showed up to 14.7% body‑weight reductions at 13 weeks, positioning it as a potential competitor or acquisition target versus Lilly and Novo Nordisk. The note highlights significant upside if Viking commercializes VK2735 but flags standard biotech risks—no current revenue base and regulatory/late‑stage trial uncertainty—making the equity speculative but of interest to risk-tolerant investors.

Analysis

Market structure: Winners include late-stage GLP-1/GIP developers (VKTX) and CDMOs/CROs supporting peptide manufacture; incumbents (NVO) retain pricing power via scale and payer relationships. The market could approach ~$100bn by 2030, but near-term supply constraints (peptide manufacture capacity) imply sustained pricing power and elevated implied vol for small-cap developers through 2026. Big pharma M&A appetite rises — expect acquisition premiums of 30–100% on successful phase‑3 results.

Risk assessment: Tail risks are binary: a negative phase‑3 or FDA safety signal could wipe out >70% of VKTX market cap within days; conversely, a clean readout or partnership could double equity within months. Time horizons: immediate (days) for headline reaction, short term (3–12 months) for partnering/M&A, long term (2–5 years) for commercial scale and reimbursement dynamics. Hidden dependencies include VKTX cash runway, supply agreements, IP freedom-to-operate, and payer coverage rules.

Trade implications: Direct: establish a small, size-constrained long in VKTX (1–3% portfolio risk) using 9–12 month OTM calls (buy Jan 2027 LEAPS or 6–12 month calls) to cap downside; hedge with 25–40% of position in protective puts or short-term put spreads. Pair: long VKTX + short a broad small‑cap biotech obesity ETF or reduce exposure to elective surgery plays by 2–3% to capture secular drug displacement. Rotate 2–4% into healthcare/biotech from consumer discretionary over next 3–6 months.

Contrarian angles: Consensus underestimates payer resistance — historical parallel: PCSK9 uptake stalled despite efficacy, suggesting realistic TAM could be 30–50% below bullish forecasts if payers limit access. The market may be overpricing green‑field entrants; incumbents’ manufacturing scale and exclusive PBM contracts could compress new entrants’ margins. Monitor CMS/NICE guidance and wholesale acquisition cost debates as potential value destroyers.

Key Decisions for Investors

• Initiate a size‑constrained tactical long in VKTX equal to 1–3% of portfolio risk: buy VKTX Jan 2027 LEAPS (or 6–12 month calls) and allocate 25–40% of that notional to protective puts; target +50–100% upside, stop-loss at −30% from entry.
• Overweight Novo Nordisk (NVO) by 2–4% as a core defensive play to capture pricing and distribution advantages; trim cyclical consumer discretionary exposure by the same amount within 30 days.
• Establish a pair trade for event risk: long VKTX + short a small‑cap obesity biotech basket (or 1–2% short of a biotech ETF with >50% exposure to early‑stage obesity assets) to isolate GLP‑1/GIP binary risk for the next 3–12 months.
• Do not add net long VKTX ahead of any announced phase‑3 readout or FDA advisory committee without buying downside protection; if a positive top‑line p3 is announced, scale into position up to 5% risk-cap within 1–2 weeks, then trim 30–50% on a 50% price move.
• Monitor 3 specific catalysts over the next 6 months — VKTX cash runway/quarterly burn, announced manufacturing/partnering deals, and any CMS/payer guidance — and reduce exposure by 50% if two of these indicators are negative.